# Crawford Lake Capital Management, LLC

> Institutional holdings reported to the SEC as of Q4 2022 on Form 13F. CIK 1623796. Source: https://holderbook.com/funds/1623796-crawford-lake-capital-management-llc/

- Reported value: $87.4M
- Positions: 15
- Weight of the ten largest: 90.9%
- Filed: 2023-02-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| STATE STR SPDR DOW JONES IND | [DIA](https://holderbook.com/stocks/DIA/) | $26.5M | 0 | 30.3% | 1 |
| BOEING CO | [BA](https://holderbook.com/stocks/BA/) | $21.0M | 10,000 | 24.0% | 1 |
| ISHARES TR | [IVW](https://holderbook.com/stocks/IVW/) | $10.2M | 174,992 | 11.7% | 1 |
| AMAZON COM INC | [AMZN](https://holderbook.com/stocks/AMZN/) | $4.8M | 57,000 | 5.5% | 1 |
| AEHR TEST SYS | [AEHR](https://holderbook.com/stocks/AEHR/) | $3.7M | 85,346 | 4.3% | 2 |
| SPLUNK INC | [SPLK](https://holderbook.com/stocks/SPLK/) | $3.6M | 42,003 | 4.1% | 1 |
| XPENG INC | [XPEV](https://holderbook.com/stocks/XPEV/) | $2.7M | 0 | 3.1% | 1 |
| ENOVIX CORPORATION | [ENVX](https://holderbook.com/stocks/ENVX/) | $2.5M | 0 | 2.9% | 2 |
| HALOZYME THERAPEUTICS INC | [HALO](https://holderbook.com/stocks/HALO/) | $2.4M | 42,171 | 2.7% | 1 |
| ON SEMICONDUCTOR CORP | [ON](https://holderbook.com/stocks/ON/) | $1.9M | 31,164 | 2.2% | 2 |
| DOCUSIGN INC | [DOCU](https://holderbook.com/stocks/DOCU/) | $1.9M | 33,500 | 2.1% | 1 |
| MONGODB INC | [MDB](https://holderbook.com/stocks/MDB/) | $1.8M | 9,350 | 2.1% | 1 |
| PROMETHEUS BIOSCIENCES INC | [RXDX](https://holderbook.com/stocks/RXDX/) | $1.7M | 15,830 | 2.0% | 1 |
| INMODE LTD | [INMD](https://holderbook.com/stocks/INMD/) | $1.7M | 0 | 1.9% | 2 |
| ISHARES TR | [FXI](https://holderbook.com/stocks/FXI/) | $863.1K | 0 | 1.0% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2022 | -22.7% | -16.5% | -6.2% | 76% |
| Q1 2022 | -24.3% | -4.9% | -19.4% | 74% |
| Q4 2021 | +0.9% | +10.7% | -9.8% | 78% |
| Q2 2021 | +7.6% | +8.0% | -0.4% | 77% |
| Q4 2020 | +6.3% | +11.6% | -5.3% | 74% |
| Q3 2020 | +20.9% | +8.6% | +12.3% | 68% |
| Q2 2020 | +37.6% | +19.6% | +18.0% | 81% |
| Q1 2020 | -19.6% | -19.9% | +0.3% | 64% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q4 2022 | $87.4M | 15 |
| Q3 2022 | $171.6M | 19 |
| Q2 2022 | $510.2M | 26 |
| Q1 2022 | $240.1M | 31 |
| Q4 2021 | $328.0M | 38 |
| Q3 2021 | $345.1M | 30 |
| Q2 2021 | $287.1M | 39 |
| Q1 2021 | $194.0M | 43 |
| Q4 2020 | $496.0M | 37 |
| Q3 2020 | $241.2M | 49 |
| Q2 2020 | $164.1M | 36 |
| Q1 2020 | $101.8M | 12 |